期刊文献+

细胞因子疗法在肿瘤治疗中的应用 被引量:1

Cytokines therapy in tumor treatment
原文传递
导出
摘要 细胞因子在肿瘤的发生发展中起着重要作用,部分细胞因子的抗肿瘤机制研究较明确。目前应用于肿瘤临床治疗的细胞因子主要有干扰素(IFN)、白细胞介素(IL)、肿瘤坏死因子(TNF)。由于细胞因子疗法作用缺乏靶向性,不良反应多导致部分患者难以耐受,细胞因子疗法临床进展受限。提高疗效稳定性、减少不良反应仍是发展肿瘤细胞因子疗法的重中之重。 Cytokines play an important role in the genesis and development of tumor. Antitumor mech- anisms of some eytokines are clearly testified. Currently, the main cytokines used in tumor clinical treatments are interferons, interleukins and tumor necrosis factors. For the lack of specificity, there are too many side effects for some patients to continue. So the application range of cytokines in tumor clinical treatment is limited. The most important measures to develop cytokines therapy are improving the stability of curative effect and reducing side effects.
出处 《国际肿瘤学杂志》 CAS 2013年第8期590-592,共3页 Journal of International Oncology
关键词 干扰素类 白细胞介素类 肿瘤坏死因子 细胞因子疗法 Interferons Interleukins Tumor necrosis factors Cytokines therapy
  • 相关文献

参考文献2

二级参考文献21

  • 1Belardelli F, Ferrantini M, Proietti E, et al. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev, 2002, 13: 119-134.
  • 2Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepati- tis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med, 1999, 131: 174-181.
  • 3Miyake Y, Iwasaki Y, Yamamoto K. Meta-analysis: reduced incidence of hepatoceUular carcinoma in patients not responding to interferon therapy of chronic hepatitis C. Int J Cancer, 2010, 127: 989-996.
  • 4Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol, 2007, 46: 45-52.
  • 5Mazzella G, Saracco G, Festi D, et al. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol, 1999, 94: 2246-2250.
  • 6Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology, 1999, 29: 971-975.
  • 7Lai CL, Lau JY, Wu PC, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology, 1993, 17: 389-394.
  • 8Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology, 2000, 31: 54-58.
  • 9Yeo W, Mok TS, Zee B, et al. A randomized phase m study of doxorubicin versus cisplatin/intefferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst, 2005, 97: 1532-1538.
  • 10Singal AK, Freeman DI-I Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther, 2010, 32: 851-858.

共引文献11

同被引文献1

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部